TGFB1 and neoplasm: Given the excellent efficacy of the triple treatment in inhibiting tumor progression, it is not surprising to us since TGFβ-1, IL-1β, and IL-10, and IL-30 are key mouse Th2, Th17, and Treg differentiation cytokines that have been linked to immune suppression during cancer development.